补肾健脾调血汤通过激活SIRT1/NRF2通路改善子宫衰老
本研究探讨补肾健脾调血汤(BJTD)改善子宫衰老的机制,采用网络药理学、体内外实验。结果显示BJTD可减轻D-半乳糖诱导的氧化应激与凋亡,其活性成分通过激活SIRT1/NRF2通路发挥作用。
要点
- BJTD可能通过激活SIRT1/NRF2通路减轻子宫衰老相关的氧化应激与凋亡。
- 体内实验显示BJTD可降低TNF-α、IL-1β水平,调节SOD、MDA、GSH-Px、T-AOC。
- 体外实验表明BJTD含药血清可改善hESC细胞凋亡,上调SIRT1、NRF2、HO-1表达。
核心结论
- BJTD可改善D-半乳糖诱导的子宫衰老模型中的氧化应激和细胞凋亡,其活性成分通过激活SIRT1/NRF2通路发挥作用。
研究设计与样本
- 采用网络药理学、体内和体外实验相结合的方法。
- 体内实验使用D-半乳糖600 mg/kg/day造模5周,BJTD干预设两个剂量。
- 体外实验使用BJTD含药血清处理人子宫内膜基质细胞(hESC)。
主要发现
- 造模5周显著增加子宫组织胶原沉积,尤其腺体和基质。
- 造模显著升高TNF-α、IL-1β水平及p53、BAX表达,降低BCL-2表达。
- BJTD显著降低TNF-α、IL-1β水平,调节SOD、MDA、GSH-Px、T-AOC等氧化应激标志物。
- BJTD抑制cleaved-Caspase 8、cleaved-Caspase 3和BAX表达。
- 体外实验显示D-Gal诱导hESC中SIRT1、NRF2、HO-1表达降低,BJTD含药血清显著上调其表达。
临床怎么用
- 对于衰老相关子宫内膜疾病,BJTD可能通过调控SIRT1/NRF2通路减轻氧化应激和凋亡。
- 临床可考虑将BJTD用于改善子宫衰老相关内分泌紊乱,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uterus ageing is a crucial factor contributing to decreased fertility in older women and is also implicated in menstrual disorders, endometritis, and adenomyosis. Bushen Jianpi Tiaoxue Decoction (BJTD) is a traditional Chinese medicine formulation used to ameliorate endocrine disorders in the female reproductive system and finds extensive application in ageing-related endometrial diseases. However, the mechanisms underlying its improvement of uterus ageing have not been thoroughly investigated. PURPOSE: To explore the potential components and mechanisms of BJTD in ameliorating uterus ageing through network pharmacology, in vivo, and in vitro experiments. METHODS: Morphological changes were observed using hematoxylin and eosin staining, collagen deposition was assessed using Masson staining, and apoptotic-related molecules were detected using Western blot. After determining the modeling doses, BJTD intervention was administered at two doses, and the expression of oxidative stress and apoptosis-related genes and proteins was measured. The levels of cellular apoptosis were evaluated using the TUNEL assay kit and Annexin V/FITC-PI assay kit. The main components of BJTD were determined by UPLC-MS, and the potential targets and mechanisms of BJTD action were explored using network pharmacology and molecular docking. BJTD-Containing Serum (BJTD-S) was extracted and applied in vitro experiments using human endometrial stroma cells (hESC) to preliminarily identify the pathways affected. RESULTS: We demonstrated that modeling with 600 mg/kg/day D-Gal for 5 weeks significantly increased collagen deposition in uterine tissues, particularly in the glands and stroma. Additionally, it significantly elevated the levels of TNF-α and IL-1β and increased the expression of p53 and BAX while decreasing BCL-2 expression. BJTD significantly reduced the increased levels of TNF-α and IL-1β induced by D-Gal, and modulated oxidative stress markers such as SOD, MDA, GSH-Px, and T-AOC. BJTD also inhibited the cascade activation of apoptosis induced by D-Gal, suppressing the expression of cleaved-Caspase 8, cleaved-Caspase 3, and BAX. SIRT1 is a potential target of BJTD action. In vitro experiments showed that BJTD-S significantly improved D-Gal-induced apoptosis in hESC cells, and the expression levels of SIRT1, NRF2, and HO-1 were significantly decreased in D-Gal-induced hESC, and BJTD-S significantly increased their expression. CONCLUSION: BJTD can ameliorate oxidative stress and cell apoptosis levels in D-Gal-induced uterine aging, and its active ingredients can activate the SIRT1/NRF2 pathway to exert its effects. Importantly, our study provides novel insights into the molecular mechanisms by which traditional Chinese medicine influence uterus ageing. By specifically targeting the SIRT1/NRF2 pathway, BJTD presents a unique therapeutic approach that has not been extensively explored in previous studies, marking a significant advancement in the treatment of uterus ageing.
引用
- Zhang J, Hu H, Zhu Y, et al. Bushen Jianpi Tiaoxue Decoction (BJTD) ameliorates oxidative stress and apoptosis induced by uterus ageing through activation of the SIRT1/NRF2 pathway. Phytomedicine. 2024. PMID: 39631297. doi:10.1016/j.phymed.2024.156288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。